STTKShattuck Labs, Inc.
7.530USD-1.70%Mkt Cap: 755.74M $P/E: —3d ago
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a de…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap755.74M $
Enterprise Value522.00M $
Revenue (TTM)1.00M $
Gross Profit-38.24M $
Net Income (TTM)-48.81M $
Revenue/Share0.0100 USD
Last Price7.530 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.07
PEG—
EV/EBITDA-10.01
EV/Revenue522.00
P/S727.63
P/B5.72
EPS (TTM)-0.42
EPS (Forward)-0.52
52W Range
0.794089% of range8.330
52W High8.330 USD
52W Low0.7940 USD
Profitability
Gross Margin0.00%
Oper. Margin-5570.50%
EBITDA Margin0.00%
Profit Margin-4880.90%
ROE-59.24%
ROA-53.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.88M $
CapEx (TTM)71.00K $
FCF Margin-2121.66%
FCF Yield-2.81%
Net Debt-205.63M $
Net Debt/EBITDA3.94
Balance Sheet
Debt/Equity0.03
Current Ratio27.59
Quick Ratio26.94
Book Value/Sh1.268 USD
Cash/Share2.075 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.25 USD
Upside (mean)+89.2%
Target Range10.00 USD – 18.00 USD
$10.00+89.2% to mean$18.00
# Analysts8
Ownership
Shares Out.100.36M
Float67.76M
Insiders4.08%
Institutions80.08%
Short Interest
Short Ratio4.9d
Short % Float6.58%
Short % Out.6.35%
Shares Short6.39M
Short (prev mo.)5.93M
Technical
SMA 506.623 (+13.7%)
SMA 2005.190 (+45.1%)
Beta1.11
S&P 52W Chg18.16%
Avg Vol (30d)1.11M
Avg Vol (10d)858.17K
Technical Indicators
RSI (14)56.4
MACD0.2213
MACD Signal0.2333
MACD Hist.-0.0120
BB Upper7.819 USD
BB Middle7.277 USD
BB Lower6.735 USD
BB Width14.90%
ATR (14)0.5209 USD
Vol Ratio (20d)0.51x